Osteoporosis Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Osteoporosis Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

Osteoporosis Drug Trends and Forecast

The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.
.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Osteoporosis Drug by Segment

The study includes a forecast for the global osteoporosis drug by drug type, application, and region.

Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others

Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Primary Osteoporosis
• Secondary Osteoporosis

Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Osteoporosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Market Insights

Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.

North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Features of the Global Osteoporosis Drug Market

Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the osteoporosis drug market size?

Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.

Q2. What is the growth forecast for osteoporosis drug market?

Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the osteoporosis drug market?

Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

Q4. What are the major segments for osteoporosis drug market?

Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.

Q5. Who are the key osteoporosis drug market companies?

Answer: Some of the key osteoporosis drug companies are as follows:

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Q6. Which osteoporosis drug market segment will be the largest in future?

Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.